News and Trends 6 Dec 2016 How is European Immuno-Oncology fighting Blood Cancer? …also announced Phase I results for IPH4102, a humanized monoclonal antibody to treat cutaneous T-cell lymphomas (CTCL), a subtype of non-Hodgkin’s lymphoma. Argenx, in the Netherlands, has two antibody… December 6, 2016 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 30 Apr 2018 Record Series B Financing Supports Antibody Cancer Therapy …of antibody-based therapies for cancer has recently been on the rise in European biotech. For example, late last year Argenx raised €195M to support the clinical development of its antibody… April 30, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jun 2020 Update: Fifth US Antibody Patent Owned by UK Biotech Upheld in Regeneron Battle Update (04/06/2020): After upholding four of Kymab’s patents addressing the production of antibody drugs earlier this year, the US Patent Trial and Appeal Board has rejected Regeneron’s attempt to invalidate… June 4, 2020 - 4 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
News and Trends 31 May 2017 German Biotech Enters the Clinic with Next-Generation Antibody for AML Synimmune has hit the clinic with a first-in-human study of its Fc-optimized antibody FlySyn to treat patients with acute myeloid leukemia (AML). The German biotech Synimmune is developing next-generation anti-cancer… May 31, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 11 Oct 2016 UK Upstart to sign Huge Deal with Takeda in End Run around Antibody Therapies …unabridged antibody counterparts, almost comparable to small peptides. Figure 1. A diagram of a whole antibody – Humabodies whittle these down to just the VH domain reflecting the antibody binding… October 11, 2016 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jan 2025 Top biotech deals of December 2024 …and development (R&D) plans. Biotech deals by approach in December 2024 Biotechs continue antibody-drug conjugates R&D streak As usual, licensing deals for antibody-drug conjugates make the cut. American pharma Gilead… January 16, 2025 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Interview 12 Feb 2018 MorphoSys’ CEO Tells Us What’s Next for Europe’s Antibody Expert …those compounds,” he continued. MorphoSys’ first attempt at taking its own antibody to market will be with its blood cancer candidate, MOR208, a monoclonal antibody that targets CD19, which is… February 12, 2018 - 8 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2017 Shire In-Licenses Swiss Antibody for Hemophilia A to Compete with Roche Shire has bought exclusive worldwide rights to develop and commercialize a bispecific antibody from Novimmune that could improve the treatment of hemophilia A. Novimmune is a biotech from Geneva that… July 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jul 2023 Epsilogen completes first clinical trial of IgE antibody to treat cancer Epsilogen, a producer of immunoglobulin E (IgE) antibodies to treat cancer, has published the final phase I data from the first ever clinical trial of an IgE antibody therapeutic. The… July 27, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Feb 2018 Is Novartis’ Psoriasis Drug Going to Steal Humira’s Crown? …million people and impacts quality of life due to its visibility. Cosentyx is a fully humanized monoclonal antibody that specifically inhibits IL-17a, a cytokine that is strongly implicated in psoriasis…. February 19, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2016 Antibody Therapies are here to Revolutionize Dermatology …royalties of up to a sweet €111.5M per antibody program. MorphoSys’ Ylanthia is the industry’s largest antibody Fab library Dermatology is an area with little innovation despite the big unmet… November 2, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2017 Phase I Results are in for Swedish Biotech’s Cancer Antibody …also signed an agreement with MAB Discovery to support its antibody pipeline. MorphoSys has looked to combine its anti-cancer antibody, MOR208, with lenalidomide – a first-line drug for lymphoma. An… November 8, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email